Table 2.
Reperfusion treatment characteristics of the sample before (pre‐COV) and after (COV) the setting of the state of emergency in Spain.
| pre‐COV (n = 492) | COV (n = 304) | P | |
|---|---|---|---|
| Reperfusion treatments per week, median (IQR) | 46.5 (39.8–60.0) | 39 (30.8–45.8) | 0.043 |
| IVT alone, n (%) | 178 (36.2) | 97 (31.9) | 0.218 |
| EVT, n (%) | 314 (63.8) | 207 (68.1) | 0.218 |
| IVT plus EVT, n (%) a | 97 (30.9) | 62 (30.0) | 0.820 |
| Anterior circulation, n (%) a | 259 (88.4) | 169 (89.9) | 0.609 |
| Tandem occlusion, n (%) a | 46 (15.5) | 27 (14.7) | 0.797 |
| General anaesthesia, n (%) a | 175 (57.0) | 81 (42.4) | 0.002 |
| First pass successful reperfusion, n (%) a | 133 (58.3) | 67 (55.4) | 0.595 |
| mTICI 2b–3, n (%) a | 290 (92.9) | 174 (86.6) | 0.016 |
EVT, endovascular treatment; IQR, interquartile range; IVT, intravenous treatment; mTICI, modified treatment in cerebral infarction; rtPA, recombinant tissue plasminogen activator. Bold font indicates statistical significance.
a
149 patients received bridging rtPA before EVT; bin EVT patients.